Market Newsdesk

HOUSTON, June 29, 2021 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational drug, Berubicin, for the treatment of patients with recurrent glioblastoma multiforme (GBM). As previously reported, the Company has also received Orphan Drug Designation from the FDA for Berubicin for the treatment of patients with recurrent GBM.

“Receiving Fast Track Designation from the U.S. FDA is a huge achievement in our advancement of Berubicin for the treatment of glioblastoma, the most aggressive, deadly and treatment-resistant type of cancer that forms in the brain. If there were ever a disease where the unmet clinical need demands action, it is GBM. Patients have almost no meaningful options and thousands lose their fight against this terrible cancer every year. With this designation, we now have an accelerated pathway to approval for Berubicin and a clear opportunity to more expediently bring this potentially impactful investigational therapy to individuals battling this challenging disease,” commented John Climaco, CEO of CNS Pharmaceuticals.

Fast Track Designation enables more frequent interactions with the FDA to expedite the development and review process for drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical need.

CNS recently announced the start of patient enrollment in its potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme. For more information about this study, please visit ClinicalTrials.gov and reference Identifier NCT04762069.

About Berubicin

Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents. Anthracyclines are designed to utilize natural processes to induce deoxyribonucleic acid (DNA) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. Berubicin treatment of brain cancer patients appeared to demonstrate positive responses that include one durable complete response in a Phase 1 human clinical trial conducted by Reata Pharmaceuticals, Inc. Berubicin, was developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

Additionally, the Company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.

For more information, please visit www.CNSPharma.com, and connect with the Company on Twitter, Facebook, and LinkedIn.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-grants-fast-track-designation-to-cns-pharmaceuticals-for-berubicin-for-the-treatment-of-recurrent-glioblastoma-multiforme-301321481.html

SOURCE CNS Pharmaceuticals, Inc.

VANCOUVER, BC, June 29, 2021 /PRNewswire/ — GreenPower Motor Company Inc. (Nasdaq: GP) (TSXV: GPV) (“GreenPower”), a leading manufacturer and distributor of zero emission electric powered vehicles serving the cargo and delivery, shuttle, transit and school bus markets, today announced financial results for its fiscal fourth quarter and year ended March 31, 2021.

Highlights of the fiscal fourth quarter:

• Recorded revenues of $4,378,131 an increase of 76% over the revenue of $2,486,669 for the fourth quarter in the previous fiscal year
• Cost of revenues were $3,210,100 generating a gross profit of $1,168,031 or 26.7% of revenues compared to a gross profit of 30.1% for the full fiscal year
• Delivered five EV250 thirty-foot all-electric buses for shuttle operations at LAX airport
• Sold 30 EV Stars to Zeem Solutions that were previously on lease with another customer
• Inventory was $12.5 million at March 31, 2021 compared to $6.6 million the previous year
• Increased production of B.E.A.S.T. all-electric school buses from five units per month to 10 units per month in response to positive feedback from demonstrations and anticipated future demand
• Cash expenses for the current quarter amounted to $2,035,699 compared to $1,909,522 for the previous quarter
• Working capital was $30,808,375 at the end of the quarter compared to $31,310,393 at the end of the previous quarter

“With the consistent run rate production for our EV Star and School Buses that was increased in Q4, we are building to meet the high demand for GreenPower products across multiple sectors including: transit, delivery, student transportation, fleet operators, municipal and final stage manufacturers,” said Brendan Riley President of GreenPower. “GreenPower has the most compelling vehicles in the medium and heavy duty, commercial EV sector. We expect strong demand for the foreseeable future.”   

Fraser Atkinson, CEO of GreenPower added, “We are excited that as the economy reopens from the Covid-19 pandemic our efforts with production have positioned us for increased deliveries, which commence this summer and accelerate thereafter.  I’m proud of our team in that we’ve been able to accomplish this with a modest increase in our quarterly cash expenses and modest decrease in working capital compared to the previous quarter.  We believe that we are on track to achieving our goal of attaining positive quarterly cash flow by the middle of the current fiscal year.”

Results for the three months ended March 31, 2021

For the three-month period ended March 31, 2021 the Company generated revenues of $4,378,131, cost of revenues of $3,210,100 yielding a gross profit of $1,168,031, related to the sale of 30 EV Stars that were previously on lease, the delivery of five EV 250s for which the Company provided lease financing and which were accounted for as finance leases, and from the sale of spare parts. Operating costs consist of administrative fees of $977,812 relating to salaries, project management, accounting, and administrative services; transportation costs of $41,558; insurance expense of $266,380; travel, accommodation, meals and entertainment costs of $38,308; product development costs of $296,164; interest and accretion of $175,450; professional fees of $210,448; as well as non-cash expenses including $1,278,194 of share-based compensation expense, allowance for credit losses of $338,818 and depreciation of $82,150. Excluding a foreign exchange loss of $69,256, the remaining operating costs for the period amounted to $135,963 in general corporate expenses and a write down of assets of $45,679, resulting in a consolidated net loss of $2,788,149.

Results for the year ended March 31, 2021

For the year ended March 31, 2021 the Company generated revenue of $11,884,578 compared to $13,500,403 for the previous year, a decrease of 12.0%. Cost of revenues of $8,304,438 yielding a gross profit of $3,580,140 or 30.1% of revenue. Revenue for the year was generated from the sale of 33 EV Stars, from the lease of 35 EV Stars, from the lease of 5 EV 250s, from lease income, and from the sale of chargers, and parts. Operating costs consist of administrative fees of $3,747,76; transportation costs of $161,017; insurance expense of $596,932; travel, accommodation, meals and entertainment costs of $217,023; product development costs of $939,949; sales and marketing costs of $234,445; interest and accretion of $1,598,588; professional fees of $486,425; as well as non-cash expenses including $2,098,761 share-based compensation expense, depreciation of $437,263, and an allowance for credit losses of $333,929. The remaining operating costs for the period amounted to $325,324 in general corporate expenses, a foreign exchange loss of $193,798 and a write down of assets of $45,679 resulting in a consolidated net loss of $7,836,754.

About GreenPower Motor Company Inc.

GreenPower designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo van and a cab and chassis.  GreenPower employs a clean-sheet design to manufacture all-electric vehicles that are purpose built to be battery powered with zero emissions while integrating global suppliers for key components. This OEM platform allows GreenPower to meet the specifications of various operators while providing standard parts for ease of maintenance and accessibility for warranty requirements. GreenPower was founded in Vancouver, Canada with primary operational facilities in southern California. Listed on the Toronto exchange since November 2015, GreenPower completed its U.S. IPO and NASDAQ listing in August 2020. For further information go to www.greenpowermotor.com

Forward-Looking Statements

This document contains forward-looking statements relating to, among other things, GreenPower’s business and operations and the environment in which it operates, which are based on GreenPower’s operations, estimates, forecasts and projections. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “upon”, “may”, “should”, “will”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. A number of important factors including those set forth in other public filings (filed under the Company’s profile on www.sedar.com) could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. Consequently, readers should not place any undue reliance on such forward-looking statements. In addition, these forward-looking statements relate to the date on which they are made. GreenPower disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. All amounts in U.S. dollars. ©2021 GreenPower Motor Company Inc. All rights reserved.

 

View original content:https://www.prnewswire.com/news-releases/greenpower-reports-fiscal-fourth-quarter-2021-financial-results-301321626.html

SOURCE GreenPower Motor Company

ROCHESTER, N.Y., June 29, 2021 /PRNewswire/ — Despite the competitive hiring environment, small business employment growth grew 0.26 percent in June, according to aggregated payroll data of approximately 350,000 clients provided by Paychex. The data released in the latest report of the Paychex | IHS Markit Small Business Employment Watch shows momentum in job growth with the Small Business Jobs Index gaining 4.53 percent during the second quarter of 2021 (in part driven by the 2020 comparison period). Hiring is particularly strong in the leisure and hospitality sector, which gained 12.65 percent in the past quarter. Hourly earnings growth increased slightly, from 2.82 percent in May to 2.84 percent in June.

“With re-openings across the country, the leisure and hospitality jobs index regained its pre-pandemic level,” said James Diffley, chief regional economist at IHS Markit.

“Following a year marked by lower employment rates, there was a notable uptick in small business jobs growth in June and throughout the second quarter. In fact, all four regions of the country experienced an increase in employment last month,” said Martin Mucci, Paychex president and CEO.

In further detail, the June report showed:

• The national index gained 0.26 percent to 98.52 in June and 4.53 percent during the second quarter of 2021.
• Employment growth in the leisure and hospitality sector increased 1.22 percent in June and 12.65 percent during the second quarter of 2021.
• Wages are also on the rise in leisure and hospitality. The sector ranks highest in hourly earnings and hours worked growth, with weekly earnings growth up double digits.
• The South continues to lead all regions in small business job growth.
• Job growth in North Carolina spiked 6.36 percent during the second quarter.
• Tampa once again leads all metros job growth.

Paychex business solutions reach 1 in 12 American private-sector employees, making the Small Business Jobs Index report an industry benchmark. The national jobs index uses a 12-month same-store methodology to gauge small business employment trends on a national, regional, state, metro, and industry basis.

The complete results for June, including interactive charts detailing all data, are available at www.paychex.com/watch. Highlights are available below. 

National Jobs Index

• The national index gained 0.26 percent to 98.52 in June and 4.53 percent during the second quarter of 2021.
• At 98.52, the jobs index has trended above 98 since April when the lower prior year employee average comparison created a base effect.

National Wage Report

• Hourly earnings growth ticked up slightly, from 2.82 percent in May to 2.84 percent in June.
• Weekly earnings growth has slowed more than one percent during the past two months due to a reduction in weekly hours worked.

Regional Jobs Index

• All four regions saw employment growth gains in June. The top-ranked region, the South, gained the least (0.05 percent). The lowest-ranked region, the Northeast, gained the most (0.45 percent).
• At 99.43, the South remained the strongest region for small business job growth, more than one point above the next highest region, the West (98.25).

Regional Wage Report

• Hourly earnings growth in the West was 3.18 percent, strongest among regions.
• Hourly earnings growth in the Northeast slowed to 2.93 percent in June.

State Jobs Index

• North Carolina has spiked 6.36 percent during the second quarter of 2021, best among states, improving its rank from 10th to 3rd.
• The bottom two states last month, Washington and Virginia, had two of the top three largest increases this month.

Note: Analysis is provided for the 20 largest states based on U.S. population.

State Wage Report

• Missouri (4.09 percent), led states in hourly earnings growth again in June, followed by Massachusetts (3.57 percent) and California (3.54 percent).
• Illinois ranks last among states in hourly earnings growth (1.70 percent) and weekly earnings growth (0.85 percent).
• Georgia remains the top state for weekly earnings growth (3.96 percent).

Note: Analysis is provided for the 20 largest states based on U.S. population.

Metropolitan Jobs Index 

• Tampa continues to lead all metros at 101.60, despite a 0.61 percent decrease in May and 0.52 percent decrease in June.
• Three of the four lowest ranked metros, San Francisco, Washington, DC., and Seattle, saw the largest increases in June.

Note: Analysis is provided for the 20 largest metro areas based on U.S. population.

Metropolitan Wage Report

• Two California metros, Riverside and Los Angeles, lead earnings growth among metros.
• Thirteen metros have hourly earnings growth below three percent.
• Seattle ranks first among metros in weekly hours worked growth, 1.44 percent.
• Due to a reduction in hours worked year-over-year, three metros have weekly earnings growth below one percent (Minneapolis, Detroit, and Baltimore).

Note: Analysis is provided for the 20 largest metro areas based on U.S. population.

Industry Jobs Index

• Leisure and hospitality gained 12.65 percent during the second quarter of 2021. Its index now ranks third among sectors.
• Construction had the largest decrease among sectors again in June (0.63 percent). This follows a decline in May of 1.78 percent.

Note: Analysis is provided for seven major industry sectors. Definitions of each industry sector can be found here. The other services (except public administration) industry category includes religious, civic, and social organizations, as well as personal services, including automotive and household repair, salons, drycleaners, and other businesses.

Industry Wage Report 

• Leisure and hospitality ranked first among sectors for earnings and hours worked growth, with weekly earnings growth up double digits.
• Other services continues to lead in employment growth; due to an influx of part-time employees. However, the sector is lowest both in hourly earnings and hours worked growth.

Note: Analysis is provided for seven major industry sectors. Definitions of each industry sector can be found here. The other services (except public administration) industry category includes religious, civic, and social organizations, as well as personal services, including automotive and household repair, salons, drycleaners, and other businesses.

For more information about the Paychex | IHS Markit Small Business Employment Watch, visit www.paychex.com/watch and sign up to receive monthly Employment Watch alerts.

*Information regarding the professions included in the industry data can be found at the Bureau of Labor Statistics website.

About the Paychex | IHS Markit Small Business Employment Watch
The Paychex | IHS Markit Small Business Employment Watch is released each month by Paychex, Inc., a leading provider of payroll, human resource, insurance, and benefits outsourcing solutions for small-to medium-sized businesses, and IHS Markit, a world leader in critical information, analytics, and expertise. Focused exclusively on small business, the monthly report offers analysis of national employment and wage trends, as well as examines regional, state, metro, and industry sector activity. Drawing from the payroll data of approximately 350,000 Paychex clients, this powerful tool delivers real-time insights into the small business trends driving the U.S. economy.

About Paychex
Paychex, Inc. (Nasdaq:PAYX) is a leading provider of integrated human capital management solutions for payroll, benefits, human resources, and insurance services. By combining its innovative software-as-a-service technology and mobility platform with dedicated, personal service, Paychex empowers small- and medium-sized business owners to focus on the growth and management of their business. Backed by 50 years of industry expertise, Paychex serves more than 710,000 payroll clients as of May 31, 2021 across more than 100 locations in the U.S. and Europe, and pays one out of every 12 American private sector employees. Learn more about Paychex by visiting paychex.com and stay connected on Twitter and LinkedIn.

About IHS Markit (www.ihsmarkit.com)
IHS Markit (NYSE: INFO) is a world leader in critical information, analytics and solutions for the major industries and markets that drive economies worldwide. The company delivers next-generation information, analytics and solutions to customers in business, finance and government, improving their operational efficiency and providing deep insights that lead to well-informed, confident decisions. IHS Markit has more than 50,000 business and government customers, including 80 percent of the Fortune Global 500 and the world’s leading financial institutions. Headquartered in London, IHS Markit is committed to sustainable, profitable growth.

IHS Markit is a registered trademark of IHS Markit Ltd. and/or its affiliates. All other company and product names may be trademarks of their respective owners © 2021 IHS Markit Ltd. All rights reserved.

Media Contacts

Lisa Fleming

Paychex, Inc.
+1 585-387-6402
[email protected] 
@Paychex 

Kate Smith

IHS Markit
+1 781-301-9311
[email protected] 

Melissa Mazurek

Mower
+1 585-389-1809
[email protected] 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/small-business-employment-gains-continue-especially-in-leisure-and-hospitality-301321875.html

SOURCE Paychex, Inc.

SAN FRANCISCO, June 29, 2021 /PRNewswire/ — Volta Industries, Inc. (“Volta Charging”), an industry leader in commerce-centric electric vehicle (EV) charging networks, has teamed up with Bloomberg Media to feature Bloomberg Green‘s climate change-focused editorial content across Volta Charging’s national network. Volta Charging will display a Bloomberg Green “Air Pollution Scoreboard” animated data visualization, a first-of-its-kind digital integration featuring localized data on the air quality in each host city updated daily. The Bloomberg Green content will run across Volta Charging’s growing network in cities such as Los Angeles, Houston, Atlanta, Chicago, Washington D.C. and New York.

Volta Charging’s unique charging stations – which feature large, eye-catching digital displays – provide an optimal content viewing experience for both the drivers who plug their vehicles into the stations and the customers who shop at near-by retailers. The Air Pollution Scoreboard is adapted from the Bloomberg Green Data Dash, a dynamic dashboard of environmental and energy metrics that provides a straightforward, highly visual way to understand what’s happening in climate developments right now. EV charging stations and the shift to electric mobility can help to reduce air pollution, making the localized air pollution data displayed on Volta Charging stations all the more pertinent.

“Our commitment to sustainability is the fuel of our business model,” said Scott Mercer, Founder and CEO of Volta Charging. “As we work to address the serious ramifications of the climate crisis, we know that it will take more than one company or one industry to spur meaningful change. Bloomberg Green shares our values and drive and we look forward to this new collaboration.”

Volta Charging’s media-enabled charging stations also offer brands a dynamic content experience platform, including activation and engagement opportunities. Brands running campaigns on Volta Charging’s stations report experiencing positive results in brand awareness and increased purchase intent; in addition, business partners who choose to have Volta Charging stations installed report an increase in spend, dwell time and engagement on site. 

“Just as Bloomberg Green provides a solutions-oriented approach to climate journalism, Volta provides new energy and clean air solutions for the automobile industry,” said Margot Schupf, Head of Americas for Bloomberg Media Distribution. “Bloomberg Media and Volta Charging share the ambition to reach like-minded audiences with deeply engaging and relevant information around critical climate issues in their community, in new and innovative ways throughout their day.”

Launched in January 2020, Bloomberg Green leverages deep data expertise and a global newsroom of 2,700 journalists and analysts in more than 120 countries, to deliver original reporting and solutions-driven coverage on the business, science, and technology of climate change. Offering news, analysis, and solutions, its content appears on the Bloomberg Green website, a daily email newsletter, a podcast, the Bloomberg Green magazine, and the Bloomberg Terminal, with integration across digital video, Bloomberg Quicktake, Bloomberg Television, Bloomberg TV+, Bloomberg Radio and Bloomberg Live events.

About Volta Charging
Volta Charging is an industry leader in commerce-centric EV charging networks. Volta Charging’s vision is to build EV charging networks that capitalize on and catalyze the shift from combustion-powered miles to electric miles by placing stations where consumers live, work, shop and play. By leveraging a data-driven understanding of driver behavior to deliver EV charging solutions that fit seamlessly into drivers’ daily routines, Volta Charging’s goal is to benefit consumers, brands and real-estate locations while helping to build the infrastructure of the future. As part of Volta Charging’s unique EV charging offering, its stations allow it to enhance its site hosts’ and strategic partners’ core commercial interests, creating a new means for them to benefit from the transformative shift to electric mobility. To learn more, visit www.voltacharging.com.

In February 2021, Volta and Tortoise Acquisition Corp. II (NYSE: SNPR), a publicly traded special purpose acquisition company with a strategic focus on energy sustainability and decarbonizing transportation, announced they entered into a business combination agreement. Upon the closing of the transaction, which remains subject to customary closing conditions, the combined entity will be named Volta Inc. and remain on the New York Stock Exchange under the new ticker symbol “VLTA”.

Bloomberg Media
Bloomberg Media is a leading, global, multi-platform brand that provides decision-makers with timely news, analysis and intelligence on business, finance, technology, climate change, politics and more. Powered by a newsroom of over 2,700 journalists and analysts, it reaches influential audiences worldwide across every platform including digital, social, TV, radio, print and live events. Bloomberg Media is a division of Bloomberg LP. Visit BloombergMedia.com for more information.

View original content to download multimedia:https://www.prnewswire.com/news-releases/volta-charging-and-bloomberg-media-team-up-for-first-of-its-kind-air-pollution-scoreboard-digital-place-based-integration-301321457.html

SOURCE Volta

NEW YORK, June 29, 2021 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for XELA, CERE, VERB, AVGR, and VBIV.

To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

• XELA: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=XELA&prnumber=062920211
• CERE: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=CERE&prnumber=062920211
• VERB: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=VERB&prnumber=062920211
• AVGR: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=AVGR&prnumber=062920211
• VBIV: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=VBIV&prnumber=062920211

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.

View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-exela-technologies-cerevel-therapeutics-verb-technology-avinger-or-vbi-vaccines-301321928.html

SOURCE InvestorsObserver

NEW YORK, June 29, 2021 /PRNewswire/ — DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, presented new clinical research today at the American Diabetes Association (ADA) 81^st Scientific Sessions, the premier diabetes conference for cutting-edge research and advances in diabetes care.

 

 

Dario’s latest research examines the impacts of the company’s artificial intelligence (AI)-driven personalization engine on user engagement and clinical outcomes for close to 10,000 members. Dario users were given access to a new product experience designed to drive better health habits and behaviors. Dario’s AI engine delivered highly personalized interventions to drive user engagement based on app activity and utilization data. The results suggest that personalized interventions help users better understand the relationship between their behaviors and their health indicators, driving sustainable engagement and better clinical outcomes. After the new digital experience was introduced, both engagement and clinical outcomes improved. The research yielded the following outcomes on 9,794 users given access to the new product experience:

• User engagement increased by 56% compared to the engagement baseline of all users before the new digital experience, results remained stable for at least six months. Average ratios of high-blood glucose readings (180-400 mg/dL) were reduced by 12% over six months.

“Consistent self-management of health conditions is one of the most crucial healthy behaviors we can help our members develop, and also one of the most difficult. Customizing the experience of health management with real-time data and feedback to offer tangible, actionable insights drives better engagement which leads to positive behavior change and improved clinical outcomes,” said Yifat Hershcovitz, Scientific and Clinical Director of DarioHealth and lead author of the study.

“This study offers yet more data supporting our personalized approach as a means to drive sustainable behavior change for improved clinical outcomes,” said Omar Manejwala, M.D., Chief Medical Officer of DarioHealth and co-author of the study.

Dario presented a second study at the ADA Scientific Sessions on the impact of Dario’s hyper-personalization platform on diabetes self-management, evaluating clinical outcomes for 11,101 high-risk Type 2 diabetic members after 12 months of engagement. The results were:

• Average ratio of target in-range readings increased significantly from 28.4% to 54.8%.
• Average number of days between blood glucose readings (Recency) for Dario members was 3.3 days

For registration inquiries or to find out how to access final program presentations, visit the ADA Scientific Sessions event website at https://professional.diabetes.org/scientific-sessions.

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market – covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform.

Dario’s next-generation, AI-powered, digital therapeutic platform supports more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software, and coaching to help individuals improve health and sustain meaningful outcomes.

Dario’s unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results.

The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and utilizes a performance-based approach to improve its users’ health.

On the path to better health, Dario makes the right thing to do the easy thing to do. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the company is using forward-looking statements in this press release when it discusses the research results and that the results demonstrate that personalized interventions help users better understand the relationship between their behaviors and their health indicators, driving sustainable engagement and better clinical outcomes. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact

Suzanne Bedell

VP Marketing
[email protected]
+1-347-767-4220

Media Contact:

Josephine Galatioto

[email protected]

+1-212-845-4262

View original content:https://www.prnewswire.com/news-releases/new-research-from-dariohealth-expands-evidence-that-personalized-interventions-impact-health-behaviors-and-improve-user-engagement-301321861.html

SOURCE DarioHealth Corp.

FREMONT, Calif., June 29, 2021 /PRNewswire/ — Enovix Corporation (“Enovix”), the leader in the design and manufacture of 3D Silicon™ Lithium-ion batteries, today announced that it will host an “Advanced Battery Production Showcase” on July 15, 2021. The virtual event, which will start at 9:00 am PDT / 12:00 pm EDT, is open to the public and will feature presentations and Q&A with Enovix leadership. Additional details and registration can be found at www.enovix.com/showcase.

The event will be broadcast live from Enovix’s factory in Fremont, California, the first facility in the world to be capable of volume production of advanced Lithium-ion batteries with a 100% active silicon anode using its 3D cell architecture. Enovix has designed, developed and sampled advanced Lithium-ion batteries with energy densities five years ahead of current industry production.

“I’m excited to introduce Enovix and our talented team to the world,” said Harrold Rust, President and Chief Executive Officer of Enovix. “Industries of the future require better batteries—and we have the leading Li-ion battery technology now. Building and scaling a 100% active silicon anode has long been the goal of the battery industry because it dramatically increases performance.”

Enovix’s proposed merger with Rodgers Silicon Valley Acquisition Corp. (Nasdaq: RSVA, RSVAU, RSVAW), announced in February 2021 (the “Business Combination”), is expected to close in July of 2021. The combined company will retain the name Enovix Corporation and will remain listed on the Nasdaq Capital Market under the new ticker symbol “ENVX.”

About Enovix

Enovix is the leader in advanced silicon-anode lithium-ion battery development and production. The company’s proprietary 3D cell architecture increases energy density and maintains high cycle life. Enovix is building an advanced silicon-anode lithium-ion battery production facility in the U.S. for volume production. The company’s initial goal is to provide designers of category-leading mobile devices with a high-energy battery so they can create more innovative and effective portable products. Enovix is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable widespread utilization of renewable energy. For more information, go to www.enovix.com.

About Rodgers Silicon Valley Acquisition Corp.

Rodgers Silicon Valley Acquisition Corp. (“RSVAC”) is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. RSVAC’s mission is to provide fundamental public technology investors with early access to an excellent Silicon Valley technology company with a focus on green energy, electrification, storage, Smart Industry (IoT), Artificial Intelligence and the new automated-manufacturing wave. For more information, go to www.rodgerscap.com.

Important Information for Investors and Stockholders

In connection with the Business Combination, RSVAC filed a registration statement on Form S-4, as amended (the “Registration Statement”) with the Securities and Exchange Commission (the “SEC”), which includes the definitive proxy statement which was distributed to holders of RSVAC’s common stock in connection with RSVAC’s solicitation of proxies for the vote by RSVAC stockholders with respect to the Business Combination and other matters as described in the Registration Statement and a prospectus relating to the offer of the securities to be issued to the equity holders of Enovix in connection with the Business Combination. The Registration Statement was declared effective by the SEC on June 24, 2021 and the definitive proxy statement/prospectus and other relevant documents have been mailed to RSVAC stockholders as of June 11, 2021. RSVAC stockholders and other interested persons are advised to read the definitive proxy statement/prospectus, in connection with RSVAC’s solicitation of proxies for the special meeting of RSVAC stockholders to be held to approve, among other things, the Business Combination, because these documents contain important information about RSVAC, Enovix and the Business Combination. RSVAC stockholders may also obtain a copy of the definitive proxy statement/prospectus, as well as other documents filed with the SEC regarding the Business Combination and other documents filed with the SEC by RSVAC, without charge, at the SEC’s website located at www.sec.gov or by directing a request to Thurman J. Rodgers, Rodgers Silicon Valley Acquisition Corp., 535 Eastview Way, Woodside, CA 94062 or by telephone at (650) 722-1753.

Participants in the Solicitation

RSVAC, Enovix and certain of their respective directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be participants in the solicitation of proxies from RSVAC stockholders in connection with the Business Combination. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of RSVAC stockholders in connection with the Business Combination, including a description of their direct and indirect interests, is set forth in the Registration Statement filed with the SEC. You can find more information about RSVAC’s directors and executive officers in the Registration Statement. You may obtain free copies of these documents from the sources indicated above.

No Offer or Solicitation

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Forward-Looking Statements

This press release contains certain forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “intend,” “future,” “may,” “to be,” “will,” “would,” “will be,” “expect,” “project,” “believe,” “estimate,” “intend,” “should,” “plan,” “predict,” “seem,” “seek,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Enovix’s ability to build and scale its advanced silicon-anode lithium-ion battery, and the expected timing of the Business Combination between Enovix and RSVAC. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Enovix and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Enovix.

These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to the rollout of the Enovix business and the timing of expected business milestones; the effects of competition on the Enovix business; and those factors discussed in the Registration Statement under the heading “Risk Factors,” and other documents RSVAC has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Enovix does not presently know, or that Enovix does not currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect the expectations, plans, or forecasts of future events by Enovix and views as of the date of this press release. Enovix anticipates that subsequent events and developments will cause the assessments of Enovix to change. However, while Enovix may elect to update these forward-looking statements at some point in the future, Enovix specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the assessments of Enovix of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Enovix gives no assurance that it will achieve its expectations.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/enovix-to-host-advanced-battery-production-showcase-301321831.html

SOURCE Enovix